Industry Analysis of Therapeutic Protein Biopharmaceuticals : 치료용 단백질 바이오 의약품 산업분석 연구

다국어 초록 (Multilingual Abstract)

The therapeutic protein sector of the pharmaceutical industry has grown rapidly since its inception in 1975 due to an increased knowledge of recombinant DNA manufacturing techniques. To date, the major players in the industry have been the biotechnology companies, but some pharmaceutical companies have realized the potential of the protein industry and have entered the market through licensing agreements and collaborations. Therapeutic proteins offer enormous potential and have already imp acted several therapeutic areas, namely cardiovascular, immunological, cancer, hematology, endocrine and viral infections. The market for therapeutic proteins is expected to reach maturity. As patents of existing proteins expire, there will be an increase in competition from generic companies which will lead to lower prices of proteins and hence decrease the growth of the market. The future of the therapeutic protein industry will depend on the
success of functional genomics for identification and validation of new therapeutic target proteins. Widespread use of recombinant DNA as a manufacturing technique has been the key driver behind the growth in the global therapeutic protein market to date. Future growth of this industry will be depend on the success of new manufacturing techniques such as trangenics and gene activation therapy. companies

국문 초록 (Abstract)

제약산업중 치료단백질분야는 DNA 재조합 제조기술에 대한 지식이 늘면서, 1975년 시작된 이래 급격히 성장했다. 현재까지는 바이오테크놀로지 회사등이 주를 이루었으며, 몇몇 제약회사들이 단백질 시장의 잠재성을 인식하고 라이센싱 계약과 제휴를 통해 시장진입을 했다. 치료용 단백질은 잠재력이 막대하며 cardiovascular, immunological, cancer, hematology , endocrine 및 viral infections등의 분야에 이미 영향을 미쳤다. 치료용 단백질 시장은 이미 성숙되었으며. 기존 단백질들의 특허가 만료됨에 따라 기존회사들의 경쟁이 심화되며 단백질 가격의 하락과 시장의 성장률을 저하하는 추세에 있다. 치료용 단백질 시장의 미래는 게놈연구로부터 단백질 의약품 신약 target을 지속적으로 발굴해 나감에 달려있다. 제조기술로서 재조합 DNA의 다양한 용도는 지금까지 세계치료 단백질 시장의 성장의 주요견인역할을 했고 미래 성장률은 transgenics 또는 gene activation therapy 등의 신 제조기술의 성공에 달려있다.

목차 (Table of Contents)

• Contents
• FIGURE AND TABLE INDEX = iii
• ABSTRACT = iv
• Ⅰ. INTRODUCT ION = 1
• Ⅱ. CURRENT MARKET SITUATION = 4
• 1. Generic protein drugs = 4
• (1) Current drugs and players = 4
• (2) Market share and growth rate = 5
• (3) Opportunities in therapeutic proteins by disease = 9
• 2. New drugs under development = 15
• (1) Aventis = 15
• (2) Chiron = 16
• (3) Millenium = 18
• (4) Human genome sciences = 19
• 3. Collaboration = 23
• 4. Manufacturing technique = 26
• (1) Blood fractionation/ tissue extraction = 26
• (2) Bacterial/ yeast fermentation = 26
• (3) Mammalian cell culture = 27
• 5. Drug delivery = 31
• (1) Routes of drug delivery = 31
• (2) Technologies and development activity = 32
• (3) Delivery of bio-pharmaceuticals 33
• Ⅲ. FUTURE PROSPECTS = 35
• 1. Impact of new manufacturing technology = 35
• (1) Transgenics 35
• 2. Gene therapy and its potential impact on protein therapy = 36
• (1) Cancer = 39
• (2) Cystic fibrosis = 40
• (3) Gaucher's disease = 41
• (4) HIV = 42
• (5) Duchenne muscular dystrophy = 42
• (6) Emphysema = 42
• (7) Gene activation therapy = 43
• Ⅳ. DISCUSSION = 45
• Ⅴ. CONCLUSION = 49
• Ⅵ. REFERENCES = 51
• ABSTRACT IN KOREAN = 53